Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT03937544 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Intravenous Autologous CD19 CAR-T Cells for R/R B-ALL

StatusRecruiting
PhasePhase 2/3
Started
View on ClinicalTrials.gov ↗

Record History

  1. Primary completion date: Mar 18, 2024 to Jan 18, 2027
    • Study completion date: Mar 18, 2024 to Mar 18, 2027
    v3
  2. Re-verified, no change to tracked fieldsv2
  3. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
This is Phase II / III, Prospective, single arm, Open Label Study to Evaluate Safety and Efficacy of Intravenous Autologous CD19 CAR-T Cells for Relapsed / Refractory B-Acute Lymphoblastic Leukaemia
Trial Details
NCT Number NCT03937544
Lead Sponsor National University of Malaysia
Collaborators: Gaia Science
Conditions
(from sponsor)		 Relapsed B Acute Lymphoblastic Leukaemia, Refractory B Acute Lymphoblastic Leukaemia
Related terms Precursor B-Cell Lymphoblastic Leukemia-Lymphoma
Enrollment 10 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov